Capital Impact Advisors’s Emergent Biosolutions EBS Stock Holding History

Capital Impact Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-24,637	Closed	-$809K	–	180
2016 Q4	$809K	Hold	24,637	–	–	0.34%	175
2016 Q3	$777K	Hold	24,637	–	–	0.34%	174
2016 Q2	$693K	Hold	24,637	–	–	0.32%	183
2016 Q1	$896K	Hold	24,637	–	–	0.43%	129
2015 Q4	$986K	Buy	24,637 +11,000	+81%	+$384K	0.47%	61
2015 Q3	$389K	Hold	13,637	–	–	0.2%	186
2015 Q2	$449K	Hold	13,637	–	–	0.2%	202
2015 Q1	$392K	Buy	13,637 +6,575	+93%	+$189K	0.18%	212
2014 Q4	$192K	Hold	7,062	–	–	0.09%	120
2014 Q3	$150	Hold	7,062	–	–	﹤0.01%	140
2014 Q2	$159K	Buy	+7,062	New	+$164K	0.12%	174

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Impact Advisors's EBS Position: Q1 2017 in Review

Capital Impact Advisors sold out of Emergent Biosolutions (EBS) in Q1 2017, closing a stake of 24,637 shares — an estimated $809K sold.

Capital Impact Advisors first reported a position in EBS in Q2 2014 and held it in 11 quarters. The position peaked at $986K in Q4 2015. 176 funds tracked by Wall St. Rank hold EBS as of Q1 2017.

Capital Impact Advisors reported no remaining Emergent Biosolutions position as of Q1 2017 after selling out during the quarter.
Capital Impact Advisors sold 24,637 Emergent Biosolutions shares in Q1 2017, an estimated $809K.
Capital Impact Advisors first reported a position in Emergent Biosolutions in Q2 2014 and held it in 11 quarters.
Capital Impact Advisors's Emergent Biosolutions position peaked at $986K in Q4 2015.
176 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2017.

Based on Capital Impact Advisors's 13F filing for Q1 2017, filed 19 Apr 2017.